Quantum Genomics S.A.

As of December 31, 2024, Quantum Genomics S.A. has 69.71M shares outstanding.

These figures are as of December 31, 2024.

These figures are as of December 31, 2024. Quantum Genomics S.A. trades at an EV/FCF ratio of 267.52, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2024, Quantum Genomics S.A. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -107.44, indicating conservative leverage, while an interest coverage ratio of -53.51 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -433.64, reflecting losses generated across the asset base.

As of the close on November 20, 2024, Quantum Genomics S.A.'s stock has declined approximately 32.62% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.09.

Quantum Genomics S.A.'s most recent stock split took place on December 13, 2013 with a 18:1 split ratio.

As of December 31, 2024, Quantum Genomics S.A. has an Altman Z-Score of -50.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.